NovImmune's primary product development platform is based on several key strategic choices:

• Selection of medically relevant and a balance of fully validated and new targets
• Choice of immune-related disorders, with unmet medical needs and large markets. Individual therapeutic mAbs developed for immune-related disorders often have multiple clinical indications, allowing multiple partnering and licensing opportunities.
• Fully human monoclonal antibodies are "best in class" therapeutic products with less immunogenicity
• NovImmune has built in-house operational excellence, for all the steps required, including sophisticated infrastructure, high throughput mAb screening and biological validation, focusing on immune-related disorders
• Priority given to the development of NovImmune's products from target selection through Phase II clinical trials. In parallel, NovImmune proposes to selected partners the possibility of co-development, offering a unique "one stop shop" covering under the same roof the entire pathway of mAb development.
• Fastest route to bringing drugs to the market